• 1
    Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46: S8289.
  • 2
    Brown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S et al . Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care 2004; 27: 11531159.
  • 3
    Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 12811289.
  • 4
    Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the UK hospital clinic population. Diabetologia 1993; 36: 150154.
  • 5
    Abbott CA, Garrow AP, Carrington AL, Morris J, Van Ross ER, Boulton AJ. Foot ulcer risk is lower in South-Asian and African-Caribbean compared with European diabetic patients in the UK: the North-West diabetes foot care study. Diabetes Care 2005; 28: 18691875.
  • 6
    Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229239.
  • 7
    Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 1999; 41: 813.
  • 8
    Valk GD, Nauta JJ, Strijers RL, Bertelsmann FW. Clinical examination vs. neruophysiological examination in the diagnosis of diabetic polyneuropathy. Diabet Med 1992; 9: 716721.
  • 9
    Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24: 250256.
  • 10
    Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002; 25: 20482052.
  • 11
    Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004; 27: 23692375.
  • 12
    Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006; 29: 6872.
  • 13
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet 1998; 352: 837853.
  • 14
    American Diabetes Association/American Academy of Neurology. Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988; 11: 592597.
  • 15
    Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H. Electrophysiological monitoring in clinical trials. Roche Neuropathy Study Group. Muscle Nerve 1998; 21: 13681373.
  • 16
    Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297334.
  • 17
    Fleiss, JL. The Design and Analysis of Clinical Experiment. New York: John Wiley & Sons Inc., 1985.
  • 18
    Agresti A. An Introduction to Categorical Data Analysis. New York: Wiley, 1996.
  • 19
    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159174.
  • 20
    England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT et al . Distal symmetric polyneuropathy: a definition for clinical research; report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64: 199207.
  • 21
    Greene DA, Arezzo JC, Brown MD, the Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999; 53: 580591.